BAILEY WULLE: Open Payments
NPI 1518731132 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,768 in 126 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $2,831 · 2025 $2,768
Food & beverage: $2,768
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $628 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $410 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $367 |
| Janssen Biotech, Inc. | 14 | $254 |
| Phathom Pharmaceuticals, Inc. | 6 | $212 |
| Lilly USA, LLC | 8 | $156 |
| GENZYME CORPORATION | 4 | $153 |
| Ardelyx, Inc. | 7 | $138 |
| Regeneron Healthcare Solutions, Inc. | 3 | $95 |
| Gilead Sciences, Inc. | 5 | $91 |
Products named: ENTYVIO, XIFAXAN, RINVOQ, TREMFYA, DUPIXENT, VOQUEZNA, SKYRIZI, OMVOH.
Industry payments across IN — which companies pay providers there.
